Christine McCrary Sisk

2.0k total citations
54 papers, 1.4k citations indexed

About

Christine McCrary Sisk is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Christine McCrary Sisk has authored 54 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Surgery, 27 papers in Endocrinology, Diabetes and Metabolism and 12 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Christine McCrary Sisk's work include Lipoproteins and Cardiovascular Health (28 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (19 papers) and Diabetes Treatment and Management (10 papers). Christine McCrary Sisk is often cited by papers focused on Lipoproteins and Cardiovascular Health (28 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (19 papers) and Diabetes Treatment and Management (10 papers). Christine McCrary Sisk collaborates with scholars based in United States, Germany and United Kingdom. Christine McCrary Sisk's co-authors include Darbie Maccubbin, Yale Mitchel, Richard C. Pasternak, Enrico P. Veltri, James M. McKenney, John F. Paolini, Aditi Sapre, Thomas Littlejohn, Daniel M. Bloomfield and Diane L. Tribble and has published in prestigious journals such as Gastroenterology, Journal of the American College of Cardiology and The American Journal of Cardiology.

In The Last Decade

Christine McCrary Sisk

53 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christine McCrary Sisk United States	21	897	588	287	205	181	54	1.4k
Matilda Florentin Greece	24	719 0.8×	584 1.0×	274 1.0×	161 0.8×	92 0.5×	73	1.7k
Teik Chye Ooi Canada	27	1.2k 1.3×	1.0k 1.7×	633 2.2×	309 1.5×	189 1.0×	79	2.4k
Anna I. Kakafika Greece	28	1.0k 1.1×	858 1.5×	496 1.7×	211 1.0×	88 0.5×	57	2.3k
Mary Jane Geiger United States	20	748 0.8×	542 0.9×	552 1.9×	237 1.2×	246 1.4×	31	2.5k
Jonathan L. Isaacsohn United States	22	1.5k 1.6×	725 1.2×	582 2.0×	289 1.4×	266 1.5×	50	2.4k
Amy O. Johnson‐Levonas United States	28	1.3k 1.4×	801 1.4×	344 1.2×	416 2.0×	333 1.8×	89	2.4k
Jorie Versmissen Netherlands	21	855 1.0×	399 0.7×	675 2.4×	331 1.6×	187 1.0×	94	2.0k
Eak Kyun Shin South Korea	31	1.3k 1.5×	1.1k 1.9×	1.3k 4.5×	254 1.2×	86 0.5×	123	3.2k
Barry Gumbiner United States	25	1.3k 1.5×	1.1k 1.9×	266 0.9×	356 1.7×	301 1.7×	51	2.7k
Pia Lundman Sweden	28	826 0.9×	770 1.3×	912 3.2×	237 1.2×	224 1.2×	70	2.5k

Countries citing papers authored by Christine McCrary Sisk

Since Specialization

Citations

This map shows the geographic impact of Christine McCrary Sisk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine McCrary Sisk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine McCrary Sisk more than expected).

Fields of papers citing papers by Christine McCrary Sisk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine McCrary Sisk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine McCrary Sisk. The network helps show where Christine McCrary Sisk may publish in the future.

Co-authorship network of co-authors of Christine McCrary Sisk

This figure shows the co-authorship network connecting the top 25 collaborators of Christine McCrary Sisk. A scholar is included among the top collaborators of Christine McCrary Sisk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine McCrary Sisk. Christine McCrary Sisk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Griesinger, Georg, Valerie Teal, Christine McCrary Sisk, & Jane Ruman. (2018). Comparison of the follicular output rate after controlled ovarian stimulation with daily recombinant follicle-stimulating hormone versus corifollitropin alfa. European Journal of Obstetrics & Gynecology and Reproductive Biology. 232. 101–105. 5 indexed citations

Nieschlag, Eberhard, Pierre-Marc Bouloux, Barbara J. Stegmann, et al.. (2017). An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism. Reproductive Biology and Endocrinology. 15(1). 17–17. 27 indexed citations

Brinton, Eliot A., Joseph Triscari, Philippe Brudi, et al.. (2016). Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes. Lipids in Health and Disease. 15(1). 116–116. 3 indexed citations

Boostanfar, R., et al.. (2016). Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial. Fertility and Sterility. 106(2). 300–305.e5. 5 indexed citations

Shentu, Yue, et al.. (2015). Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial. Drugs & Aging. 32(6). 469–476. 24 indexed citations

Rahe‐Meyer, Niels, Hein Fennema, Sam Schulman, et al.. (2015). Effect of Reversal of Neuromuscular Blockade With Sugammadex Versus Usual Care on Bleeding Risk in a Randomized Study of Surgical Patients. Survey of Anesthesiology. 59(6). 278–279. 10 indexed citations

Kosoglou, Teddy, Paul Statkevich, Bhavna Kantesaria, et al.. (2014). Vorapaxar, an oral PAR‐1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone. Clinical Pharmacology in Drug Development. 4(1). 56–62. 2 indexed citations

Maccubbin, Darbie, et al.. (2013). Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. International Journal of Clinical Practice. 67(4). 297–302. 33 indexed citations

Norquist, Josephine M., Christine McCrary Sisk, Kelly McQuarrie, et al.. (2013). The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy. International Journal of Clinical Practice. 67(12). 1238–1246. 8 indexed citations

10.

Teramoto, Tamio, et al.. (2012). EFFICACY AND SAFETY OF THE CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR ANACETRAPIB AS MONOTHERAPY AND COADMINISTERED WITH ATORVASTATIN IN JAPANESE PATIENTS WITH DYSLIPIDEMIA. Journal of the American College of Cardiology. 59(13). E1689–E1689.

11.

Maccubbin, Darbie, Fabian Chen, Jennifer Anderson, et al.. (2012). Effectiveness and Safety of Laropiprant on Niacin-Induced Flushing. The American Journal of Cardiology. 110(6). 817–822. 11 indexed citations

12.

Bays, Harold, Arvind Shah, Jianxin Lin, et al.. (2012). Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups. American Journal of Cardiovascular Drugs. 12(3). 197–206. 15 indexed citations

13.

Wagner, Frank, Marie‐Pierre Malice, Erol Wiegert, et al.. (2012). A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans. Journal of Hypertension. 30(4). 819–827. 11 indexed citations

14.

Seck, Thomas, Samuel S. Engel, Debora Williams‐Herman, et al.. (2011). Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Research and Clinical Practice. 93(1). e15–e17. 20 indexed citations

15.

Dansky, Hayes M., Daniel M. Bloomfield, Patrice H. Gibbons, et al.. (2011). Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia. American Heart Journal. 162(4). 708–716. 24 indexed citations

16.

Bays, Harold, Alexandra A. MacLean, Arvind Shah, et al.. (2010). The Lipid-Altering Effects of Extended-Release Niacin/Laropiprant Among Different Patient Subgroups. Journal of clinical lipidology. 4(3). 215–215. 1 indexed citations

17.

Maccubbin, Darbie, Michael J. Koren, Michael Davidson, et al.. (2009). Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease. The American Journal of Cardiology. 104(1). 74–81. 57 indexed citations

18.

Paolini, John F., Yale Mitchel, Rafael Reyes, et al.. (2008). Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire©: results from a randomised placebo-controlled clinical trial. International Journal of Clinical Practice. 62(6). 896–904. 14 indexed citations

19.

Paolini, John F., Harold Bays, Christie M. Ballantyne, et al.. (2008). Extended-Release Niacin/Laropiprant: Reducing Niacin-Induced Flushing to Better Realize the Benefit of Niacin in Improving Cardiovascular Risk Factors. Cardiology Clinics. 26(4). 547–560. 23 indexed citations

20.

Pearson, Thomas A., Christie M. Ballantyne, Christine McCrary Sisk, et al.. (2007). Comparison of Effects of Ezetimibe/Simvastatin Versus Simvastatin Versus Atorvastatin in Reducing C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels. The American Journal of Cardiology. 99(12). 1706–1713.e1. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact